Clinical Trial Update: Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM). [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating vildagliptin for functional improvement of progenitor cells and endothelial function in diabetes mellitus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Johann Wolfgang Goethe University Hospital | Conditions: SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors | Phase 2, Phase 3 | Status: WITHDRAWN